Kadouche; Jean

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kadouche; Jean.The latest application filed is for "multispecific antibodies".

Company Profile

4.10.14

Kadouche; Jean - Paris FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Multispecific Antibodies App 20210040235 - Kadouche; Jean ; et al.	2021-02-11
Multispecific Antibodies App 20200385490 - Kadouche; Jean ; et al.	2020-12-10
Multispecific antigen binding fragments and multispecific antibodies derived therefrom comprising mutant CH1 and CL-kappa domains Grant 10,815,310 - Kadouche , et al. October 27, 2	2020-10-27
Multispecific Antigens Binding Fragments And Multispecific Antibodies Derived Therefrom Comprising Mutant Ch1 And Cl-kappa Domains App 20180022829 - Kadouche; Jean ; et al.	2018-01-25
Multispecific antigens binding fragments and multispecific antibodies derived therefrom comprising mutant CH1 and CL-.kappa. domains Grant 9,631,031 - Kadouche , et al. April 25, 2	2017-04-25
Multispecific Mutated Antibody Fab Fragments App 20140242076 - Kadouche; Jean ; et al.	2014-08-28
Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof Grant 8,728,477 - Kadouche , et al. May 20, 2	2014-05-20
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells Grant 8,409,573 - Boumsell , et al. April 2, 2	2013-04-02
Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells App 20110311544 - Boumsell; Laurence ; et al.	2011-12-22
Anti-cd 160 Monoclonal Antibodies And Uses Thereof App 20110280866 - Didierlaurent; Denis ; et al.	2011-11-17
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells Grant 7,736,647 - Boumsell , et al. June 15, 2	2010-06-15
Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof App 20090074657 - Kadouche; Jean ; et al.	2009-03-19
Chimeric Anti Cd44 Antibodies and Their Use for Treating Acute Myeloid Leukemia App 20070237761 - Smadja; Florence ; et al.	2007-10-11
Use of anti-ferritin monoclonal antibodies in the treatment of some cancers (divisional) App 20070042447 - Kadouche; Jean ; et al.	2007-02-22
Use of anti-ferritin monoclonal antibodies in the treatment of some cancers Grant 7,153,506 - Kadouche , et al. December 26, 2	2006-12-26
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells App 20060286030 - Boumsell; Laurence ; et al.	2006-12-21
Automatic large-scale screening of cells secreting monoclonal antibodies App 20060141538 - Kadouche; Jean ; et al.	2006-06-29
Drug delivery system App 20050180997 - Benita, Simon ; et al.	2005-08-18
Use of anti-ferritin monoclonal antibodies in the treatment of some cancers App 20020106324 - Kadouche, Jean ; et al.	2002-08-08

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.